Mount Sinai School of Medicine In-house Grant

Previous evidence suggests that the modification of the methylation status and histone deacetylases (HDAC) in cancer cells has positive anti-tumoral effects. This study will evaluate the role of HDAC inhibitors in experimental models of HCC, as a proof-of-principle to conduct early clinical trials in humans.